CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
14.73 CAD
+0.21 (+1.45%)
CPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. While CPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. CPH is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
In the past year CPH had a positive cash flow from operations.
In the past 5 years CPH has always been profitable.
CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CPH has a better Return On Assets (7.97%) than 87.50% of its industry peers.
CPH has a better Return On Equity (11.10%) than 87.50% of its industry peers.
With an excellent Return On Invested Capital value of 5.17%, CPH belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 7.94%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROIC | 5.17% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
CPH's Profit Margin of 25.52% is amongst the best of the industry. CPH outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
CPH has a Operating Margin of 20.32%. This is amongst the best in the industry. CPH outperforms 90.63% of its industry peers.
CPH's Operating Margin has declined in the last couple of years.
The Gross Margin of CPH (73.79%) is better than 93.75% of its industry peers.
CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
The number of shares outstanding for CPH has been increased compared to 1 year ago.
CPH has less shares outstanding than it did 5 years ago.
CPH has a worse debt/assets ratio than last year.
2.2 Solvency
CPH has an Altman-Z score of 5.10. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
CPH has a better Altman-Z score (5.10) than 93.75% of its industry peers.
CPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, CPH is in line with its industry, outperforming 53.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.1 |
ROIC/WACC0.65
WACC7.94%
2.3 Liquidity
CPH has a Current Ratio of 1.72. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
CPH's Current ratio of 1.72 is in line compared to the rest of the industry. CPH outperforms 46.88% of its industry peers.
CPH has a Quick Ratio of 1.41. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CPH (1.41) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
CPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.47% on average per year.
The Revenue has grown by 114.76% in the past year. This is a very strong growth!
The Revenue has been growing by 8.25% on average over the past years. This is quite good.
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
The Earnings Per Share is expected to grow by 13.99% on average over the next years. This is quite good.
Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 21.67% on average per year.
EPS Next Y105.37%
EPS Next 2Y20.78%
EPS Next 3Y13.99%
EPS Next 5YN/A
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.66, which indicates a rather expensive current valuation of CPH.
Based on the Price/Earnings ratio, CPH is valued cheaper than 84.38% of the companies in the same industry.
CPH is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.29, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 15.97, CPH is valued correctly.
78.13% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
CPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.85, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.66 | ||
| Fwd PE | 15.97 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 62.50% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.7 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPH may justify a higher PE ratio.
CPH's earnings are expected to grow with 13.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)1.82
EPS Next 2Y20.78%
EPS Next 3Y13.99%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (10/16/2025, 7:00:00 PM)
14.73
+0.21 (+1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap372.96M
Analysts77.78
Price Target17.87 (21.32%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)2
Avg EPS beat(4)-14.13%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)6
Avg EPS beat(8)67.23%
EPS beat(12)10
Avg EPS beat(12)112.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)3
Avg Revenue beat(4)31.13%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)115.89%
Revenue beat(8)5
Avg Revenue beat(8)22.37%
Revenue beat(12)5
Avg Revenue beat(12)11.03%
Revenue beat(16)5
Avg Revenue beat(16)5.52%
PT rev (1m)0%
PT rev (3m)9.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)46.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.66 | ||
| Fwd PE | 15.97 | ||
| P/S | 5.58 | ||
| P/FCF | N/A | ||
| P/OCF | 12.56 | ||
| P/B | 2.43 | ||
| P/tB | 15.89 | ||
| EV/EBITDA | 16.7 |
EPS(TTM)0.65
EY4.41%
EPS(NY)0.92
Fwd EY6.26%
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)1.17
OCFY7.96%
SpS2.64
BVpS6.07
TBVpS0.93
PEG (NY)0.22
PEG (5Y)1.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROCE | 7.18% | ||
| ROIC | 5.17% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 22.78% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 1132.75% | ||
| Cap/Sales | 168.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.25% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 5.1 |
F-Score5
WACC7.94%
ROIC/WACC0.65
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
EPS Next Y105.37%
EPS Next 2Y20.78%
EPS Next 3Y13.99%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year111.58%
EBIT Next 3Y37.67%
EBIT Next 5YN/A
FCF growth 1Y-558.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3Y12.28%
OCF growth 5Y19.77%